Michael Ulz
Stock Analyst at Morgan Stanley
(4.54)
# 257
Out of 5,055 analysts
101
Total ratings
55.74%
Success rate
28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $29 → $45 | $40.15 | +12.08% | 5 | Nov 12, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $90 → $94 | $73.26 | +28.31% | 8 | Oct 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $98 → $102 | $38.22 | +166.88% | 4 | Oct 23, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $75 → $81 | $72.21 | +12.17% | 4 | Oct 16, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $25 → $21 | $5.79 | +262.69% | 8 | Oct 9, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $405 → $475 | $460.54 | +3.14% | 12 | Oct 6, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $6.70 | +273.13% | 12 | May 9, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $7.16 | +179.33% | 2 | Apr 1, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $2.39 | +820.50% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $10.36 | +179.92% | 1 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $2.42 | +726.45% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $1.43 | +599.30% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $54.34 | +76.68% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $20.24 | +156.92% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $0.97 | +619.42% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $12.06 | +123.88% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $1.45 | +1,279.31% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.04 | +1,380.26% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.72 | +1,280.45% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $4.12 | -27.18% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $5.49 | +446.45% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $500 | $27.72 | +1,703.75% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $32.54 | +145.85% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $9.42 | +59.24% | 3 | Jul 12, 2017 |
Arrowhead Pharmaceuticals
Nov 12, 2025
Maintains: Equal-Weight
Price Target: $29 → $45
Current: $40.15
Upside: +12.08%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $94
Current: $73.26
Upside: +28.31%
Viking Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $38.22
Upside: +166.88%
Mirum Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $75 → $81
Current: $72.21
Upside: +12.17%
Karyopharm Therapeutics
Oct 9, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $5.79
Upside: +262.69%
Alnylam Pharmaceuticals
Oct 6, 2025
Maintains: Equal-Weight
Price Target: $405 → $475
Current: $460.54
Upside: +3.14%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $6.70
Upside: +273.13%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $7.16
Upside: +179.33%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $2.39
Upside: +820.50%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $10.36
Upside: +179.92%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.42
Upside: +726.45%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.43
Upside: +599.30%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $54.34
Upside: +76.68%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $20.24
Upside: +156.92%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $0.97
Upside: +619.42%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $12.06
Upside: +123.88%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $1.45
Upside: +1,279.31%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.04
Upside: +1,380.26%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.72
Upside: +1,280.45%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $4.12
Upside: -27.18%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $5.49
Upside: +446.45%
May 28, 2020
Maintains: Outperform
Price Target: $300 → $500
Current: $27.72
Upside: +1,703.75%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $32.54
Upside: +145.85%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $9.42
Upside: +59.24%